Comparison of the therapeutic effects of paclitaxel liposome-5-Fu versus paclitaxel-5-Fu on 67 patients with advanced gastric cancer.
- Author:
Fang WU
1
;
Shu-chang CHEN
;
Zhi-hui LU
;
Jian-ping XIONG
Author Information
- Publication Type:Clinical Trial
- MeSH: Adult; Antineoplastic Agents, Phytogenic; administration & dosage; adverse effects; Antineoplastic Combined Chemotherapy Protocols; adverse effects; therapeutic use; Disease Progression; Female; Fluorouracil; administration & dosage; Follow-Up Studies; Humans; Liposomes; Male; Nausea; chemically induced; Paclitaxel; administration & dosage; adverse effects; Remission Induction; Stomach Neoplasms; drug therapy; pathology; Survival Rate; Vomiting; chemically induced
- From: Chinese Journal of Oncology 2010;32(3):234-236
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the efficacy, time to disease progression (TTP), overall survival (OS) and toxicity of paclitaxel liposome versus paclitaxel combined with 5-fluorouracil (5-Fu) for patients with advanced gastric cancer.
METHODSThe therapeutic efficacy of chemotherapy with either of the two regimens for 67 cases of naïve advanced gastric cancer was analyzed. Among them, 31 patients in the paclitaxel liposome-5-Fu group received paclitaxel liposome 175 mg/m(2) d1, CF 200 mg/m(2) d1, 5-Fu 2.6 g/m(2) civ. 46 hours, 21 days as one cycle, and 34 patients in the paclitaxel-5-Fu group received paclitaxel 175 mg/m(2) d1, CF 200 mg/m(2) d1, 5-Fu 2.6 g/m(2) civ. 46 hours, 21 days as one cycle.
RESULTSThe objective response rate was 54.8% in the paclitaxel liposome group and 44.1% in the paclitaxel group (P = 0.388). The median time to progression was 5.10 months vs. 5.20 months (P = 0.266) and the median survival time was 10.07 months vs. 8.97 months (P = 0.186). The most frequent side-effects were nausea, vomit and hematological toxicities. The rates of grade III-IV nausea and vomit were 16.1% and 50.0% (P = 0.038), muscle and joint pain were 9.7% and 29.4% (P = 0.047).
CONCLUSIONBoth regimens are effective in the treatment of advanced gastric cancer. However, less adverse effects occur in the paclitaxel liposome group.
